Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cyp2d63, 4, 5 and 6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.

Clinical and experimental pharmacology & physiology - 1 Jul 2008

Crescenti Anna, Mas Sergi, Gassó Patricia, Parellada Eduard, Bernardo Miquel, Lafuente Amalia

Abstract excerpt

1. The aim of the present study was to examine the relationship between CYP2D6 polymorphisms and the risk of antipsychotic (AP)-induced extrapyramidal symptoms (EPS) in patients receiving AP treatment. The allele status for CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*6 was determined in 267 patients receiving AP therapy. Seventy-nine cases presenting with EPS (Simpson-Angus Scale 3) and 188 controls without EPS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Basal Ganglia Diseases

Share to Cohort Studies

Share to Cytochrome P-450 CYP2D6

Share to Dyskinesia, Drug-Induced

Share to Genotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 18346175
DOI: 10.1111/j.1440-1681.2008.04918.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.PMID 18346175Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Semantic proximity Read ↗

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.Semantic proximity Read ↗

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.Semantic proximity Read ↗

Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.Semantic proximity Read ↗

CYP 2D6 polymorphism and antipsychotic therapy.Semantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

CYP2D6 mutations and therapeutic outcome in schizophrenic patients.Semantic proximity Read ↗

CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effectsSemantic proximity Read ↗

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.Semantic proximity Read ↗

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.